Abstract
There is increasing interest in utilizing novel markers of cardiovascular disease risk and consequently, there is a need to assess the value of their use. In this paper, we will review the role of biomarkers in acute coronary syndromes, heart failure and risk stratification for cardiovascular events as guide for treatment scribing. In particular, high sensitivity assays for troponin evaluation detect with greater precision patients with elevated troponin. Therefore, direct and appropriate management is succeeded in these patients with reduction of complications due to earlier treatment, as well. Regarding heart failure, randomized trials that have evaluated biomarker guided treatment approach have not succeeded in establishing specific results for natriuretic peptides (BNP, NT-proBNP) use in terms of therapy guidance. Apart from them, a variety of novel or already used biomarkers, have been tested by small trials for heart failure management, without however, managing to dominate in every day care. Finally, as far as risk stratification for cardiovascular events is concerned, hsCRP has proved to be a strong but doubted biomarker. Therefore, lifestyle and behavioral modification remain the cornerstone of primary prevention.
Keywords: cTnI, cTnT, BNP, NT-proBNP, hsCRP, cardiovascular disease, coronary syndromes, troponin, biomarker, biological molecules
Current Medicinal Chemistry
Title:Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Volume: 19 Issue: 16
Author(s): M. Vavuranakis, M. G. Kariori, K. I. Kalogeras, D. A. Vrachatis, C. Moldovan, D. Tousoulis and C. Stefanadis
Affiliation:
Keywords: cTnI, cTnT, BNP, NT-proBNP, hsCRP, cardiovascular disease, coronary syndromes, troponin, biomarker, biological molecules
Abstract: There is increasing interest in utilizing novel markers of cardiovascular disease risk and consequently, there is a need to assess the value of their use. In this paper, we will review the role of biomarkers in acute coronary syndromes, heart failure and risk stratification for cardiovascular events as guide for treatment scribing. In particular, high sensitivity assays for troponin evaluation detect with greater precision patients with elevated troponin. Therefore, direct and appropriate management is succeeded in these patients with reduction of complications due to earlier treatment, as well. Regarding heart failure, randomized trials that have evaluated biomarker guided treatment approach have not succeeded in establishing specific results for natriuretic peptides (BNP, NT-proBNP) use in terms of therapy guidance. Apart from them, a variety of novel or already used biomarkers, have been tested by small trials for heart failure management, without however, managing to dominate in every day care. Finally, as far as risk stratification for cardiovascular events is concerned, hsCRP has proved to be a strong but doubted biomarker. Therefore, lifestyle and behavioral modification remain the cornerstone of primary prevention.
Export Options
About this article
Cite this article as:
Vavuranakis M., G. Kariori M., I. Kalogeras K., A. Vrachatis D., Moldovan C., Tousoulis D. and Stefanadis C., Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases, Current Medicinal Chemistry 2012; 19 (16) . https://dx.doi.org/10.2174/092986712800492977
DOI https://dx.doi.org/10.2174/092986712800492977 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Tissue Factor and Hypertension
Current Hypertension Reviews Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
Current Vascular Pharmacology Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis
Current Medicinal Chemistry Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Alpha-2 Agonists: Can they Modify the Outcomes in the Postanesthesia Care Unit?
Current Drug Targets Endoplasmic Stress Inhibitors for Homocysteine Induced Cardiovascular Disease
Current Pharmaceutical Design Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective
Current Hypertension Reviews Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents
Current Cardiology Reviews